(Q38101381)

28 August 2017

title

The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma (English)

1 reference

28 August 2017

Roman Hajek

1

0 references

Athanasios Dimopoulos

object named as

Meletios Dimopoulos

series ordinal

6

0 references

Antonio Palumbo

series ordinal

5

object named as

Antonio Palumbo

1 reference

28 August 2017

4

Heinz Ludwig

1 reference

28 August 2017

3

Robert Z Orlowski

1 reference

28 August 2017

David Siegel

2

1 reference

28 August 2017

publication date

12 June 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

55

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

11-18

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

28 August 2017

1 reference

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Changing paradigms in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Recent major improvement in long-term survival of younger patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Clinical course of patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Histone deacetylase inhibitors: Potential in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Intracellular protein degradation and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

The novel histone deacetylase inhibitor, AR‐42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Vorinostat enhances the antimyeloma effects of melphalan and bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Vorinostat in solid and hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

HDAC modulation and cell death in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Identification of novel isoform-selective inhibitors within class I histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.797084

10.3109/10428194.2013.797084

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference